Estate Counselors LLC Makes New $4.43 Million Investment in Edwards Lifesciences Corporation $EW

Key Points

• Estate Counselors LLC has invested approximately $4.43 million in Edwards Lifesciences Corporation, acquiring 61,130 shares, which constitutes about 0.5% of its portfolio.
• Analyst ratings for Edwards Lifesciences are generally positive, with a consensus rating of "Moderate Buy" and a price target of $85.90.
• In the latest quarterly earnings report, Edwards Lifesciences exceeded analysts' expectations with an EPS of $0.67 and reported a revenue of $1.53 billion, marking an 11.9% increase year-over-year.

Estate Counselors LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 61,130 shares of the medical research company's stock, valued at approximately $4,431,000. Edwards Lifesciences accounts for approximately 0.5% of Estate Counselors LLC's portfolio, making the stock its 29th biggest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Prosperity Consulting Group LLC grew its position in shares of Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after buying an additional 134 shares during the last quarter. Arlington Trust Co LLC grew its position in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after buying an additional 135 shares during the last quarter. Valeo Financial Advisors LLC grew its position in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after buying an additional 142 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after buying an additional 145 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.1%

Shares of EW traded up $0.06 on Tuesday, reaching $80.92. The stock had a trading volume of 843,234 shares, compared to its average volume of 4,495,265. The firm has a market capitalization of $47.51 billion, a price-to-earnings ratio of 11.65, a price-to-earnings-growth ratio of 3.95 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a 50-day simple moving average of $77.71 and a 200-day simple moving average of $74.79. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the sale, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,584 shares of company stock valued at $1,897,762. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a research report on Tuesday, July 29th. Piper Sandler lifted their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Finally, The Goldman Sachs Group restated a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.